TY - JOUR AU - Wokke, J. H. AU - Escolar, D. M. AU - Pestronk, A. PY - 2008 DA - 2008// TI - Clinical features of late-onset Pompe disease: a prospective cohort study JO - Muscle Nerve VL - 38 UR - https://doi.org/10.1002/mus.21025 DO - 10.1002/mus.21025 ID - Wokke2008 ER - TY - CHAP AU - Engel, A. G. AU - Hirschhorn, R. ED - Engel, A. G. ED - Franzine-Armstrong, C. PY - 1996 DA - 1996// TI - Acid maltase deficiency BT - Myology: basic and clinical PB - McGraw-Hill CY - New York ID - Engel1996 ER - TY - JOUR AU - Ploeg, A. T. AU - Reuser, A. J. PY - 2008 DA - 2008// TI - Pompe's disease JO - Lancet VL - 372 UR - https://doi.org/10.1016/S0140-6736(08)61555-X DO - 10.1016/S0140-6736(08)61555-X ID - Ploeg2008 ER - TY - CHAP AU - Hirschhorn, R. AU - Reuser, A. J. ED - Scriver, C. K. ED - Beaudet, A. L. ED - Sly, W. S. PY - 2001 DA - 2001// TI - Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency BT - The metabolic & molecular bases of inherited disease PB - McGraw-Hill CY - New York ID - Hirschhorn2001 ER - TY - JOUR AU - Beek, N. A. AU - Hagemans, M. L. AU - Reuser, A. J. PY - 2009 DA - 2009// TI - Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease JO - Neuromuscul Disord VL - 19 UR - https://doi.org/10.1016/j.nmd.2008.11.007 DO - 10.1016/j.nmd.2008.11.007 ID - Beek2009 ER - TY - JOUR AU - Mellies, U. AU - Stehling, F. AU - Dohna-Schwake, C. AU - Ragette, R. AU - Teschler, H. AU - Voit, T. PY - 2005 DA - 2005// TI - Respiratory failure in Pompe disease: treatment with noninvasive ventilation JO - Neurology VL - 64 UR - https://doi.org/10.1212/01.WNL.0000158682.85052.C0 DO - 10.1212/01.WNL.0000158682.85052.C0 ID - Mellies2005 ER - TY - JOUR AU - Winkel, L. P. AU - Hagemans, M. L. AU - Doorn, P. A. PY - 2005 DA - 2005// TI - The natural course of non-classic Pompe's disease; a review of 225 published cases JO - J Neurol VL - 252 UR - https://doi.org/10.1007/s00415-005-0922-9 DO - 10.1007/s00415-005-0922-9 ID - Winkel2005 ER - TY - JOUR AU - Baldo, B. A. PY - 2015 DA - 2015// TI - Enzymes approved for human therapy: indications, mechanisms and adverse effects JO - Bio Drugs VL - 29 ID - Baldo2015 ER - TY - JOUR AU - Schoser, B. AU - Hill, V. AU - Raben, N. PY - 2008 DA - 2008// TI - Therapeutic approaches in glycogen storage disease type II/Pompe disease JO - Neurotherapeutics VL - 5 UR - https://doi.org/10.1016/j.nurt.2008.08.009 DO - 10.1016/j.nurt.2008.08.009 ID - Schoser2008 ER - TY - JOUR AU - Ploeg, A. T. AU - Clemens, P. R. AU - Corzo, D. PY - 2010 DA - 2010// TI - A randomized study of alglucosidase alfa in late-onset Pompe's disease JO - N Engl J Med VL - 362 UR - https://doi.org/10.1056/NEJMoa0909859 DO - 10.1056/NEJMoa0909859 ID - Ploeg2010 ER - TY - JOUR AU - Kishnani, P. S. AU - Corzo, D. AU - Nicolino, M. PY - 2007 DA - 2007// TI - Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease JO - Neurology VL - 68 UR - https://doi.org/10.1212/01.wnl.0000251268.41188.04 DO - 10.1212/01.wnl.0000251268.41188.04 ID - Kishnani2007 ER - TY - JOUR AU - Lim, J. A. AU - Li, L. AU - Raben, N. PY - 2014 DA - 2014// TI - Pompe disease: from pathophysiology to therapy and back again JO - Front Aging Neurosci VL - 6 UR - https://doi.org/10.3389/fnagi.2014.00177 DO - 10.3389/fnagi.2014.00177 ID - Lim2014 ER - TY - JOUR AU - Kishnani, P. S. AU - Beckemeyer, A. A. PY - 2014 DA - 2014// TI - New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond JO - Pediatr Endocrinol Rev VL - 12 ID - Kishnani2014 ER - TY - JOUR AU - Nicolino, M. AU - Byrne, B. AU - Wraith, J. E. PY - 2009 DA - 2009// TI - Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease JO - Genet Med VL - 11 UR - https://doi.org/10.1097/GIM.0b013e31819d0996 DO - 10.1097/GIM.0b013e31819d0996 ID - Nicolino2009 ER - TY - JOUR AU - Kornfeld, S. PY - 1990 DA - 1990// TI - Lysosomal enzyme targeting JO - Biochem Soc Trans VL - 18 UR - https://doi.org/10.1042/bst0180367 DO - 10.1042/bst0180367 ID - Kornfeld1990 ER - TY - JOUR AU - Zhu, Y. AU - Li, X. AU - McVie-Wylie, A. PY - 2005 DA - 2005// TI - Carbohydrate-remodelled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice JO - Biochem J VL - 389 UR - https://doi.org/10.1042/BJ20050364 DO - 10.1042/BJ20050364 ID - Zhu2005 ER - TY - JOUR AU - McVie-Wylie, A. J. AU - Lee, K. L. AU - Qiu, H. PY - 2008 DA - 2008// TI - Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease JO - Mol Genet Metab VL - 94 UR - https://doi.org/10.1016/j.ymgme.2008.04.009 DO - 10.1016/j.ymgme.2008.04.009 ID - McVie-Wylie2008 ER - TY - JOUR AU - Tong, P. Y. AU - Kornfeld, S. PY - 1989 DA - 1989// TI - Ligand interactions of the cation-dependent mannose 6-phosphate receptor. Comparison with the cation-independent mannose 6-phosphate receptor JO - J Biol Chem VL - 264 ID - Tong1989 ER - TY - JOUR AU - Maga, J. A. AU - Zhou, J. AU - Kambampati, R. PY - 2013 DA - 2013// TI - Glycosylation-independent lysosomal targeting of acid alpha-glucosidase enhances muscle glycogen clearance in pompe mice JO - J Biol Chem VL - 288 UR - https://doi.org/10.1074/jbc.M112.438663 DO - 10.1074/jbc.M112.438663 ID - Maga2013 ER - TY - STD TI - Safety/Tolerability/Pharmacokinetic (PK)/Pharmacodynamics (PD) Study of BMN701 in Patients With Late-Onset Pompe Disease. In: ClinicalTrialsgov [internet] Bethesda (MD): National Library of Medicine (US) 2000- [cited 2015 Aug 07] Accessed 18 Nov 2016; Available from: http://bit.ly/2g3Pubc NLM Identifier: NCT01230801. UR - http://bit.ly/2g3Pubc ID - ref20 ER - TY - STD TI - Extension Study for Patients Who Have Participated in a BMN 701 Study. In: ClinicalTrialsgov [internet] Bethesda (MD): National Library of Medicine (US) 2000- [cited 2015 Aug 07] Accessed 18 Nov 2016; Available from: http://bit.ly/2foq1Wa Identifier: NCT01435772. UR - http://bit.ly/2foq1Wa ID - ref21 ER - TY - JOUR AU - Fuller, D. D. AU - ElMallah, M. K. AU - Smith, B. K. PY - 2013 DA - 2013// TI - The respiratory neuromuscular system in Pompe disease JO - Respir Physiol Neurobiol VL - 189 UR - https://doi.org/10.1016/j.resp.2013.06.007 DO - 10.1016/j.resp.2013.06.007 ID - Fuller2013 ER - TY - JOUR AU - LeBowitz, J. H. AU - Grubb, J. H. AU - Maga, J. A. AU - Schmiel, D. H. AU - Vogler, C. AU - Sly, W. S. PY - 2004 DA - 2004// TI - Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice JO - Proc Natl Acad Sci U S A VL - 101 UR - https://doi.org/10.1073/pnas.0308728100 DO - 10.1073/pnas.0308728100 ID - LeBowitz2004 ER - TY - STD TI - SIP P. Phenotype variations in early onset Pompe disease: diagnosis and treatment results with Myozyme®. In: Inherited neuromuscular diseases. Netherlands: Springer; 2009. p. 39–46. ID - ref24 ER - TY - JOUR AU - Merk, T. AU - Wibmer, T. AU - Schumann, C. AU - Kruger, S. PY - 2009 DA - 2009// TI - Glycogen storage disease type II (Pompe disease)--influence of enzyme replacement therapy in adults JO - Eur J Neurol VL - 16 UR - https://doi.org/10.1111/j.1468-1331.2008.02377.x DO - 10.1111/j.1468-1331.2008.02377.x ID - Merk2009 ER - TY - JOUR AU - Burrow, T. A. AU - Bailey, L. A. AU - Kinnett, D. G. AU - Hopkin, R. J. PY - 2010 DA - 2010// TI - Acute progression of neuromuscular findings in infantile Pompe disease JO - Pediatr Neurol VL - 42 UR - https://doi.org/10.1016/j.pediatrneurol.2010.02.006 DO - 10.1016/j.pediatrneurol.2010.02.006 ID - Burrow2010 ER - TY - JOUR AU - Ploeg, A. T. AU - Barohn, R. AU - Carlson, L. PY - 2012 DA - 2012// TI - Open-label extension study following the late-onset treatment study (LOTS) of alglucosidase alfa JO - Mol Genet Metab VL - 107 UR - https://doi.org/10.1016/j.ymgme.2012.09.015 DO - 10.1016/j.ymgme.2012.09.015 ID - Ploeg2012 ER - TY - JOUR AU - Kishnani, P. S. AU - Goldenberg, P. C. AU - DeArmey, S. L. PY - 2010 DA - 2010// TI - Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants JO - Mol Genet Metab VL - 99 UR - https://doi.org/10.1016/j.ymgme.2009.08.003 DO - 10.1016/j.ymgme.2009.08.003 ID - Kishnani2010 ER - TY - JOUR AU - Banugaria, S. G. AU - Patel, T. T. AU - Mackey, J. PY - 2012 DA - 2012// TI - Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells JO - Mol Genet Metab VL - 105 UR - https://doi.org/10.1016/j.ymgme.2012.01.019 DO - 10.1016/j.ymgme.2012.01.019 ID - Banugaria2012 ER - TY - JOUR AU - Messinger, Y. H. AU - Mendelsohn, N. J. AU - Rhead, W. PY - 2012 DA - 2012// TI - Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease JO - Genet Med VL - 14 UR - https://doi.org/10.1038/gim.2011.4 DO - 10.1038/gim.2011.4 ID - Messinger2012 ER - TY - JOUR PY - 2002 DA - 2002// TI - ATS/ERS statement on respiratory muscle testing JO - Am J Respir Crit Care Med VL - 166 UR - https://doi.org/10.1164/rccm.166.4.518 DO - 10.1164/rccm.166.4.518 ID - ref31 ER - TY - JOUR AU - Evans, J. A. AU - Whitelaw, W. A. PY - 2009 DA - 2009// TI - The assessment of maximal respiratory mouth pressures in adults JO - Respir Care VL - 54 ID - Evans2009 ER - TY - JOUR AU - Farrero, E. AU - Antón, A. AU - Egea, C. J. PY - 2013 DA - 2013// TI - Guidelines for the management of respiratory complications in patients with neuromuscular disease JO - Arch Bronconeumol VL - 49 UR - https://doi.org/10.1016/j.arbres.2012.12.003 DO - 10.1016/j.arbres.2012.12.003 ID - Farrero2013 ER - TY - JOUR AU - Mendoza, M. AU - Gelinas, D. F. AU - Moore, D. H. AU - Miller, R. G. PY - 2007 DA - 2007// TI - A comparison of maximal inspiratory pressure and forced vital capacity as potential criteria for initiating non-invasive ventilation in amyotrophic lateral sclerosis JO - Amyotroph Lateral Scler VL - 8 UR - https://doi.org/10.1080/17482960601030188 DO - 10.1080/17482960601030188 ID - Mendoza2007 ER - TY - JOUR AU - Johnson, E. M. AU - Roberts, M. AU - Mozaffar, T. AU - Young, P. AU - Quartel, A. AU - Berger, K. I. PY - 2016 DA - 2016// TI - Pulmonary function tests (maximum inspiratory pressure, maximum expiratory pressure, vital capacity, forced vital capacity) predict ventilator use in late-onset Pompe disease JO - Neuromuscul Disord VL - 26 UR - https://doi.org/10.1016/j.nmd.2015.11.009 DO - 10.1016/j.nmd.2015.11.009 ID - Johnson2016 ER - TY - JOUR AU - Estenne, M. AU - Gevenois, P. A. AU - Kinnear, W. AU - Soudon, P. AU - Heilporn, A. AU - Troyer, A. PY - 1993 DA - 1993// TI - Lung volume restriction in patients with chronic respiratory muscle weakness: the role of microatelectasis JO - Thorax VL - 48 UR - https://doi.org/10.1136/thx.48.7.698 DO - 10.1136/thx.48.7.698 ID - Estenne1993 ER - TY - JOUR AU - Roberts, M. AU - Kishnani, P. S. AU - Ploeg, A. T. PY - 2011 DA - 2011// TI - The prevalence and impact of scoliosis in Pompe disease: lessons learned from the Pompe registry JO - Mol Genet Metab VL - 104 UR - https://doi.org/10.1016/j.ymgme.2011.08.011 DO - 10.1016/j.ymgme.2011.08.011 ID - Roberts2011 ER - TY - JOUR AU - Bergofsky, E. H. PY - 1979 DA - 1979// TI - Respiratory failure in disorders of the thoracic cage JO - Am Rev Respir Dis VL - 119 ID - Bergofsky1979 ER - TY - JOUR AU - Koumbourlis, A. C. PY - 2006 DA - 2006// TI - Scoliosis and the respiratory system JO - Paediatr Respir Rev VL - 7 UR - https://doi.org/10.1016/j.prrv.2006.04.009 DO - 10.1016/j.prrv.2006.04.009 ID - Koumbourlis2006 ER - TY - JOUR AU - Beek, N. A. AU - Capelle, C. I. AU - Velden-van Etten, K. I. PY - 2011 DA - 2011// TI - Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease JO - Mol Genet Metab VL - 104 UR - https://doi.org/10.1016/j.ymgme.2011.06.012 DO - 10.1016/j.ymgme.2011.06.012 ID - Beek2011 ER - TY - JOUR AU - Deehan, M. AU - Garces, S. AU - Kramer, D. PY - 2015 DA - 2015// TI - Managing unwanted immunogenicity of biologicals JO - Autoimmun Rev VL - 14 UR - https://doi.org/10.1016/j.autrev.2015.02.007 DO - 10.1016/j.autrev.2015.02.007 ID - Deehan2015 ER -